Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study

Daniel Podzamczer(Bellvitge University Hospital), The TORAL Study Group, Eugènia Negredo(Universitat de Vic - Universitat Central de Catalunya), Vicente Estrada(Instituto de Salud Carlos III), Antonio Ocampo(University Hospital Complex Of Vigo), Ignacio de los Santos, Hernando Knobel(Hospital General de Granollers), Marı́a Jesús Pérez-Elı́as(Hospital Universitario Ramón y Cajal), Joaquín Portilla(Hospital General Universitario de Alicante Doctor Balmis), Jordi Curto(Bellvitge University Hospital), Josefa Galindo, Peré Domingo(Hospital de Sant Pau), Pompeyo Viciana(Apple (Israel)), Estebán Martínez(Instituto de Salud Carlos III), Manuel Castaño, Antonio Antela(Universidade de Santiago de Compostela), Jorge Carmena, Esteban Ribera(Hospital Terrassa), Ferrán Segura(Corporació Sanitària Parc Taulí), Elena Ferrer(Hospital Universitari Germans Trias i Pujol)
Current HIV Research
November 8, 2012
10.2174/157016212803901428
Cited by 3

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
|New England Journal of Medicine|2023|476
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
|The Lancet HIV|2020|396